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Radial Primary Angioplasty
The Gold Standard Treatment for STEMI Patients*
Carlo Di Mario, MD, PHD, Gioel Secco, MD
London, United Kingdom
We are ﬂooded with studies on new drugs or devices
because they attract commercial sponsorship. If their results
show small incremental beneﬁts compared with existing
tools, immediate changes in guidelines and practice are
requested by self-appointed opinion leaders, irrespective of
the cost and compatibility for a sustainable health system.
Mamas et al. (1) show a highly signiﬁcant 29% reduction
in 30-day mortality in 46,128 ST-segment elevation
myocardial infarction (STEMI) patients using the radial
access site, a huge beneﬁt that comes with no additional
cost. Radial angioplasty was introduced 20 years ago by
Kiemeneij et al. (2), and immediately showed advantages in
terms of reduction in bleeding, patient discomfort, and
hospital stay. Small-scale studies also suggest improvements
in hard endpoints, especially in acute coronary syndromesSee page 698(ACS). Yet, we had to wait 15 years before a trial with
more than 7,000 patients, a sufﬁcient number to detect
outcome changes, showed a signiﬁcant 61% reduction in
mortality at 30 days in the STEMI radial subgroup (3).
Because this reduction was not consistent in all ACS
patients and the primary endpoint was not met, results
could not be considered conclusive (4). The smaller Italian
RIFLE-STEACS (Radial Versus Femoral Randomization
Investigation in ST-Elevation Acute Coronary Syndrome)
trial (5), with 1,001 patients, found a signiﬁcant reduction
in mortality in the radial group, but mortality in the femoral
group was abnormally high (5.2% vs. 9.2%; p ¼ 0.020).
Despite the strong message from a meta-analysis with
2,977 patients (6), new conﬁrmatory trials were requested.
We would probably have had to wait another 20 years if the
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opportunity of providing new data. Combined, this now
includes almost 160,000 STEMI patients with consistent
results, revealing a 22% reduction in the adjusted one-year
cumulative risk of death in 21,339 STEMI patients in the
SCAAR (Swedish Coronary and Angioplasty Registry) (7),
and a 24% reduction in in-hospital mortality in the 90,879
NCDR (National Cardiovascular Data Registry) U.S.
patients (8). Nevertheless, this paper does not solve the
radial paradox: What is the mechanism of the mortality
improvement? How can radial angioplasty induce a reduc-
tion in mortality over and above the reduction in major
bleeding and vascular complications? The investigators
blame underestimation and lack of data auditing on
bleeding. But these considerations also apply to the radial
substudies of the RIVAL (Radial Versus Femoral
Access for Coronary Intervention) (3) and HORIZONS
(Harmonizing Outcomes With Revascularization and
Stents) trials (9), which were fully monitored and highly
focused on bleeding events. Without a clear mechanistic
explanation and rationale, it is difﬁcult to convince the
skeptics that changes observed are not caused by differences
in the radial and femoral patient groups. A major
confounder can be the natural urge for experienced radial
operators to turn to the femoral in a hemodynamically
unstable patient, for whom you expect there is a chance to
insert a balloon pump during or after angioplasty. In the
recent SHOCK (Should We Emergently Revascularize
Occluded Coronaries for Cardiogenic Shock) trial (10),
mortality is still 40%, unfortunately, it is not helped by the
use of intra-aortic balloon pump. Clustering of high-risk
patients in the femoral group is not easy to correct with
statistical adjustments. The U.K. radial operators in this
registry had differences in concomitant treatment, which
not everybody would agree might result in a mortality
beneﬁt. They used glycoprotein IIb/IIIa inhibitors and
manual thrombectomy more frequently. Whereas glyco-
protein IIb/IIIa inhibitors might be “out-of-fashion,” in
a clinical scenario where almost all patients were anti-
coagulated with heparin and very few received novel
antiplatelet agents, especially in the early years of data
collection, it is hard to argue with countless publications
and meta-analysis in favor of these drugs (11). Reluctance
to add the strongest and most rapid platelet inhibitors at
our disposal even when there is high thrombus burden or
slow ﬂow during angioplasty, because fear of bleeding at the
access site, may be deleterious. We are awaiting the results
of large trials on manual thrombectomy, but the general
view is that you do not need to treat everybody with
thrombectomy. Still, radial operators perform thrombec-
tomy more liberally than femoral operators do, reﬂecting an
attitude of avoiding shortcuts. Whereas a rapid time to
reperfusion is important, when ﬂow is re-established,
patience, a common virtue of radialists, and liberal use of
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708adjuvant vasodilators, often already used by radialists to
prevent spasm, may facilitate spontaneous thrombolysis and
limit reperfusion injury through minimal technical differ-
ences. No Cox regression or propensity analysis can catch
these subtle differences in practice.
The BCIS-NICOR (British Cardiovascular Intervention
Society–National Institute for Clinical Outcomes Research)
registry has an advantage over previous publications. Like
SCAAR (7), it collects nationwide data and is not limited to
selected centers. This study was conducted in a phase of
rapid change in “access” policy, with radial angioplasty
increasing from 12.5% in 2006 to 49.5% in 2010. Mamas
et al. (1) do not correlate outcome with individual operator
or center utilization using the radial approach. Still the
message is clear, switching to a wide-scale radial policy,
which necessarily means inclusion of operators and centers
in a relatively early learning phase, still offers an advantage in
mortality. This relatively high presence of initial adopters
may explain the reason why outcome changes are not as large
as in other registries and trials. However, it overrides the
common belief that the radial approach is only helpful if you
are a fully committed radial operator and center and elimi-
nates the last excuse for operators and centers unwilling to
change, despite overwhelming clinical evidence. Training is
obviously still essential, and it is inconceivable to use a radial
approach in an acute STEMI patient alone, in the middle of
the night, without adequate experience of more predictable
“simple” diagnostic and angioplasty cases. Young trainees
must be trained in radial angioplasty and STEMI treatment
using radial angioplasty, and these numbers should be
separately collected. Mature operators should feel a moral
obligation in learning new basic skills that will increase
their performance (12). In the end, the 2012 European
Society of Cardiology STEMI guidelines give a strong
Class IIa Level B recommendation for radial angioplasty
(13). Training and proctorship are universally accepted
prerequisites for performing transcatheter aortic valve
replacement implantation. So why not develop skills that, in
absolute terms, will probably save more lives?Reprint requests and correspondence: Dr. Carlo DiMario, Royal
Brompton Hospital, Sydney Street, London SW3 6NP, United
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